BioCryst Pharmaceuticals Inc
NASDAQ:BCRX

Watchlist Manager
BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Watchlist
Price: 7.6 USD 1.47% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
BioCryst Pharmaceuticals Inc?
Write Note

BioCryst Pharmaceuticals Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BioCryst Pharmaceuticals Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Gross Profit
$404.6m
CAGR 3-Years
56%
CAGR 5-Years
109%
CAGR 10-Years
36%
Abbvie Inc
NYSE:ABBV
Gross Profit
$37.3B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$22B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$12B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
17%
No Stocks Found

BioCryst Pharmaceuticals Inc
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 358 full-time employees. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The firm has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.

BCRX Intrinsic Value
11.3 USD
Undervaluation 33%
Intrinsic Value
Price

See Also

What is BioCryst Pharmaceuticals Inc's Gross Profit?
Gross Profit
404.6m USD

Based on the financial report for Sep 30, 2024, BioCryst Pharmaceuticals Inc's Gross Profit amounts to 404.6m USD.

What is BioCryst Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
36%

Over the last year, the Gross Profit growth was 30%. The average annual Gross Profit growth rates for BioCryst Pharmaceuticals Inc have been 56% over the past three years , 109% over the past five years , and 36% over the past ten years .

Back to Top